氟伐他汀对代谢综合征患者骨密度的影响

目的探讨氟伐他汀对代谢综合征患者骨密度的影响。方法63例代谢综合征患者随机分为氟伐他汀组（n=32）及对照组（n=31），两组病例均予治疗性生活方式转变（therapeutic lifestyle changes，TLC）干预。治疗前及治疗36周后分别检测腰椎骨密度（BMD—LS）、股骨颈骨密度（BMD—Fn）、股骨近端骨密度（BMD-Ftot）及血脂谱。结果氟伐他汀组在治疗后36周BMD—LS、BMD—Fn、BMD—Ftot分别升高了3．1％、1．3％、1．0％，对照组分别下降了1．8％、1．6％、1．4％，两组各参数比较差异有显著性意义（P〈0．05）；氟伐他汀组总胆固醇（Tc）、低密度脂蛋白胆固醇（LDL-C）、甘油三酯（TG）分别降低了25．7％、37．9％、23．4％，高密度脂蛋白胆固醇（HDL）升高了8．0％，与对照组比较差异有显著性意义（P〈0．05）。结论氟伐他汀能提高代谢综合征患者的骨密度。

Effects of fluvastatin on bone mineral density in patients with metabolic syndrome

Objective To evaluate the effect of flurvastatin on bone density in patients with metabolic syndrome.Methods Sixty-three patients with metabolic syndrome were randomly divided to fluvastatin-treated group(n=32) and control group(n=31).The bone mineral density at the lumbar spine(BMD-LS),femoral neck(BMD-Fn) and the proximal end of the femur(BMD-Ftot) was measured by dual energy X-ray densitometry before and after 36 weeks of treatment between both groups.The blood samples were collected for determination of lipid profile.Results There were a significant increase of BMD-LS,BMD-Fn and BMD-Ftot in fluvastatin-treated group than in control group(P < 0.05).The lipid-lowering effect of fluvastatin was confirmed with a decrease of 25.7 %,37.9 %,23.4 %,and an increase of 8.0 % in serum total cholesterol,low density lipoprotein-cholesterol,triglyceride,and high density lipoprotein-cholesterol respectively.Conclusion Fluvastatin is favorable to the increase of bone mineral density in patients with metabolic syndrome.